breast cancer - HR positive | |||
la/mBC - HR-positive - 2nd line (L2) | la/mBC - HR positive - L2 - all population | la/mBC - HR positive - L2 - PIK3CA mutant | |
buparlisib plus fulvestrant | BELLE-3 | BELLE-2 ... | BELLE-2 ... |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -